A study by Sonali et al., 2013 suggested that the co-administration of CYP3A4 and CYP2D6 interacting drugs not significantly might partially be involved in the plasma concentration of anti-AD drugs like donepezil to a clinically significant extent (Perry and Howes, 2011; Auxtero et al., 2021). Here, CYP3A4 is linked to Alzheimer disease.